AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$252.66-0.78%
Close 2026-07-08 · 1-day change
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→QuarterlyIQ Insights · ABBV
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(2.4) + peer(0.2*7.1) + term(0.0) → 2.26% (capped ±15.0)
in 23 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 8 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 29, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: February 4, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2025 have not been finalized and are subject to our financial statement closing procedures.…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2025 have not been finalized and are subject to our financial statement closing procedures.…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: July 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. The…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 25, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. The…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: January 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures.…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 30, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2024 are expected to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2024 have not been finalized and are subject to our financial statement closing procedures.…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: July 25, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer